Research Article

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Table 1

The prognostic value of the mRNA expression of ERCC in different clinical stage GC patients.

GenesStagecasesHR (95% CI)P-value

ERCC1I390.31 (0.1–0.94)0.029
II491.54 (0.62–3.78)0.35
III2170.83 (0.6–1.15)0.26
IV772.64 (1.48–4.71)0.00068
ERCC2I393.17 (0.96–10.44)0.046
II490.57 (0.21–1.55)0.26
III2171.35 (0.95–1.91)0.096
IV741.89 (1.06–3.36)0.028
ERCC3I392.68 (0.73–9.87)0.12
II490.46 (0.19–1.07)0.065
III2171.25 (0.9–1.75)0.19
IV740.75 (0.43–1.32)0.32
ERCC4I395.03 (1.11–22.74)0.02
II493.29 (139.–7.77)0.0043
III2171.45 (0.98–2.13)0.063
IV740.72 (0.41–1.27)0.25
ERCC5I390.29 (0.06–1.32)0.088
II490.36 (0.13–0.99)0.038
III2171.27 (0.87–1.85)0.22
IV740.57 (0.31–1.04)0.065
ERCC6I397.09 (0.91–55.24)0.03
II492.84 (1.22–6.62)0.012
III2171.23 (0.86–1.76)0.26
IV740.62 (0.35–1.09)0.095
ERCC8I340.23 (0.06–0.83)0.015
II441.68 (0.65–4.34)0.28
III1091.46 (0.91–2.36)0.12
IV660.66 (0.37–1.2)0.17

Notes. ERCC, excision repair cross-complementing; GC, gastric cancer; HR, hazard ratio; CI, confidence interval.